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Beta-blockers and the treatment of hypertension:  
it is time to move on
tensive treatment was commenced with a beta-blocker than for 
those who received a renin-angiotensin system inhibitor [rela-
tive risk increase (RRI) 30%, 95% CI 11–53%] or a calcium 
channel blocker (RRI 24%, 95% CI 11–40%). In addition, the 
risk of death from any cause (RRI 7%, 95% CI 0–14%) and any 
cardiovascular event (RRI 18%, 95% CI 8–29%) was higher for 
patients on beta-blockers than those on calcium channel block-
ers.3 It has also been shown that beta-blockers significantly 
increase the risk of new-onset diabetes compared to placebo 
(RRI 25%, 95% CI 5–50%), renin-angiotensin system inhibitors 
and calcium channel blockers.7 
When medication costs and the costs associated with treat-
ment of hypertension-related and antihypertensive-induced 
complications are considered, beta-blockers are less cost-effec-
tive than thiazide diuretics, renin-angiotensin system inhibitors 
and calcium channel blockers.8 
It is important to note that the current evidence derives 
mainly from trials of first- and second-generation beta-block-
ers (mainly atenolol), as there are no outcome data yet on 
third-generation beta-blockers.3 The sub-optimal cardiovascular 
protection with conventional (ie, first- and second-generation) 
beta-blockers may be due to the development of new-onset 
diabetes and the inability to decrease central aortic pressure 
as much as brachial pressure.9 In theory, third-generation 
beta-blockers should reduce central blood pressure more than 
conventional beta-blockers because vasodilatation by the former 
may alter the pattern of the pressure wave reflecting back from 
the periphery.9,10 In addition, the newer beta-blockers may have 
a better metabolic profile.10
Clinicians should use the currently available scientific 
evidence3,7,8 to guide the management of their patients with 
hypertension but this does not yet seem to be the case. Beta-
blockers are still widely used worldwide. For example, 12 to 
29% of patients on antihypertensive drugs in various European 
countries are on beta-blockers, a substantial proportion on aten-
olol.11 We think it is now time to move on. There is a need for 
long-term, outcome-randomised, controlled trials to compare 
the effects of third-generation beta-blockers10 with those of 
renin-angiotensin system inhibitors and calcium channel block-
ers. In the meantime, guideline developers should no longer 
recommend beta-blockers for initiating antihypertensive treat-
ment. 
Similarly, conventional beta-blockers should no longer be 
used as comparator drugs in randomised, controlled hyperten-
sion trials. We do, however, acknowledge that some patients 
with hypertension may require beta-blockers for symptomatic 
angina, chronic stable heart failure and post-myocardial infarc-
Editorial
Existing solid scientific evidence with hard outcome data should 
be the basis for treatment guidelines, and where such evidence is 
lacking, we must invest in research.1 A case in point is the initia-
tion of antihypertensive treatment with a beta-blocker.2-4 
Beta-blockers are pharmacological agents that block the 
action of endogenous catecholamines on beta-adrenergic recep-
tors, part of the sympathetic nervous system which mediates 
the ‘fight or flight’ response. The main adrenergic receptors 
present in human cardiovascular tissues are the β1-, β2-, and 
α1-receptors.5 β1-adrenergic receptors are located mainly in the 
heart and kidneys and β2-receptors are found mainly in the lungs 
and gastrointestinal tract. The α1-receptors mediate endothelial 
function and vasoconstriction in peripheral blood vessels and 
regulate blood flow to the kidney. 
Beta-blockers differ with regard to β1/β2-adrenergic receptor 
selectivity and vasodilatory activity, and these differences have 
led to their subdivision into first-, second- and third-generation 
agents. First-generation beta-blockers, such as propranolol and 
pindolol, are termed non-selective since they exert equal block-
ade of β1- and β2-receptors. The second-generation beta-block-
ers (such as atenolol and metoprolol) are described as selective 
because they exhibit higher affinity for β1- than β2-adrenergic 
receptors. Finally, third-generation beta-blockers (eg, carvedilol 
and nebivolol) differ from first- and second-generation beta-
blockers in their vasodilatory properties.5
Beta-blockers have been routine treatment for patients with 
hypertension for several decades, apparently because activation 
of the sympathetic nervous system is important in the aetiol-
ogy and maintenance of hypertension.6 We recently re-assessed 
the effectiveness and safety of these pharmacological agents 
when used as first-line treatment for hypertension.3,4 Evidence 
from randomised, controlled trials published by 1992 show that 
hypertensive patients who were treated with a first- to second-
generation beta-blocker for a median duration of about five 
years had their relative risk (RR) of stroke and all cardiovascular 
events reduced by 20% [95% confidence interval (CI) 4–34%] 
and 12% (95% CI 3–21%), respectively, compared to those on 
placebo or no treatment. These effects of beta-blockers were 
similar to those of thiazide diuretics, but patients were more 
likely to withdraw from a beta-blocker due to the side effects 
than a diuretic (RR 86%, 95% CI 39–150%).
However, between 2002 and 2005, scientific evidence rapid-
ly accumulated to show that the cardiovascular protection and 
safety profile of beta-blockers was inferior to that of newer 
antihypertensive agents such as calcium channel blockers and 
inhibitors of the renin-angiotensin system. The incidence of 
stroke was significantly higher for patients whose antihyper-
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tion protection, or as part of multiple therapy for resistant 
hypertension.8,12,13 
The United Kingdom National Institute for Health and 
Clinical Excellence and the British Hypertension Society have 
taken the bull by the horns and downgraded beta-blockers 
from first- to fourth-line antihypertensive drugs, ie, add-on 
drugs in patients requiring multiple therapy.8 The South African 
Hypertension Society has made a similar recommendation.14 
While other hypertension guidelines have not (yet) been updated 
in the light of the current evidence,15 the European Society of 
Hypertension and the European Society of Cardiology still over-
look the current evidence and recommend the use of any anti-
hypertensive agent (including beta-blockers) for initiation and 
maintenance of antihypertensive treatment, alone or in combina-
tion.16 However, the American Heart Association has just recom-
mended that for patients at high risk of coronary artery disease, 
such as those with diabetes, chronic renal disease, or a 10-year 
Framingham risk score of 10% or higher, first antihypertensive 
choices should exclude beta-blockers.17
In summary, beta-blockers are effective in preventing cardio-
vascular disease but are no longer suitable for routine initial 
treatment of hypertension because their cardiovascular protection 
and metabolic effects are worse than those of other antihyper-
tensive drugs. However, it is time to move on, and randomised, 
controlled, hypertension outcome trials are needed to prove the 
non-inferiority of the newer vasodilating beta-blockers (such as 
nebivolol and carvedilol) in comparison with renin-angiotensin 
system inhibitors and calcium channel blockers. 
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